The Ministry of Health is negotiating the purchase of a coronavirus vaccine with the Indian manufacturer Serum Institute.
In particular, the Serum Institute can produce vaccines Novavax and AstraZeneca, said Deputy Minister of Health Ihor Ivashchenko, Interfax-Ukraine reports.
However, he did not specify whether it was about the purchase of a vaccine that is being developed by the Serum Institute, or about vaccines from other companies.
Coronavirus vaccines being considered by Ukraine
BioNTech / Pfizer vaccine
The vaccine of the German company BioNTech and the American concern Pfizer was the first to be approved by WHO. It was this vaccine that also began to be used in the EU for mass vaccination of the population. About 19 countries are going to vaccinate the population with the BioNTech and Pfizer vaccine.
In particular, Ukraine can receive 100,000 doses of vaccine from BioNTech and Pfizer as part of a program aimed to distribute the vaccine in poor countries.
The Ministry is also in talks with Moderna to get a coronavirus vaccine. In December 2020, this medication was approved for use in the United States. And on January 6, it was approved by the EU. In 2021, it is planned to produce about 1 billion doses.
The AstraZeneca vaccine was developed by a Swedish-British pharmaceutical manufacturer in collaboration with the University of Oxford. The vaccine has already been approved for use in the UK, India, and Argentina. The vaccine is going to be produced in India—it is planned to produce 3 billion doses in 2021.
The vaccine from the Chinese company Sinovac Biotech (CoronaVac) is 100% effective in preventing severe cases of COVID-19, almost 78% effective in preventing mild cases, and has an overall effectiveness of 50.4%.
It is the Sinovac vaccine that will be produced by the Ukrainian company Lekhim. It received from a Chinese company a quota for 5 million doses of vaccine in order to sell them in Ukraine in the first half of 2021, 1.9 million doses of them the Ministry of Health wants to purchase .
Johnson & Johnson vaccine
The Johnson & Johnson vaccine performed well during the last phase of clinical trials. More than 90% of participants in trials after vaccination produced immune proteins within 29 days.
In addition, this vaccine only needs to be administered once.
The Ministry of Health is also negotiating with Johnson & Johnson on the vaccine purchase.